Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
chemotherapy
The Three Rs Of Cancer Survival
By gdpawel at 2011-05-31 07:06
 

Solid tumours such as brain tumours are highly resistant to chemotherapyterm and radiation. One reason for this is a ‘reduce, reuse, recycle’ strategy that these tumours use to survive treatment. By developing a cancer drug that targets this recycling pathway, Malaghan Institute of Medical Research scientists have struck upon a novel approach for combating otherwise resistant and aggressive cancers.

read more | 19103 reads

Common chemotherapy drug triggers fatal allergic reactions
By Dross at 2009-06-10 03:21
 

Patients with curable early stage breast cancer died from chemotherapyterm solvent

CHICAGO -- A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.

read more | 9 comments | 7326 reads

McGill researchers overcome chemotherapy resistance in the lab
By Dross at 2008-06-28 22:20
 

Re-purposed Malaysian folk medication reduces resistance to cancer treatments

Researchers from McGill University’s Faculty of Medicine have discovered a compound that reduces resistance to chemotherapyterm agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI).

Dr. Jerry Pelletier, PhD candidate Marie-Eve Bordeleau, and post-doctoral fellow Francis Robert, of the Department of Biochemistry and the McGill Cancer Centre – along with colleagues from Boston University, the Sloan-Kettering Cancer Center, the University of Vienna and the Howard Hughes Medical Institute – conducted an extensive study on a class of natural products known as cyclopenta benzofuran flavaglines (CBF).

read more | 1883 reads

Explaining chemotherapy-associated nausea
By Dross at 2008-01-30 20:58
 

A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapyterm. The findings could lead to the development of new approaches to combat these debilitating side effectsterm.

“By increasing knowledge of what causes the nausea and vomiting that accompany chemotherapy treatment, we move closer to providing patients with less traumatic and hopefully more effective drug treatment regimens,” said lead author Bart De Jonghe, PhD, a Monell physiologist.

Anorexia (loss of appetite) and cachexia (a syndrome of physical wasting and weight loss) often accompany chemotherapy-induced symptoms of nausea and vomiting. These side effects can compromise the patient’s nutritional status and impede recovery.

read more | 2 comments | 2874 reads

Antiemetics, Their Function, and Their Role in Controlling Chemotherapy-Induced Nausea and Vomiting
By HCat at 2007-10-19 09:45
 

    Because chemotherapyterm is such a harsh treatment on the body, the body reacts to these poisonous chemicals and tries to rid the body of them. One way the body responds is through a vomiting action preceded by a nausea feeling. Because the continuation of treatment is critical in chemotherapy and since nausea and vomiting is a common side effect, antiemetics are used to prevent or lessen the nausea and vomiting mechanisms. Antiemetics are compounds that prevent emesis, otherwise known as vomiting. Antiemetics function through various molecular pathways and are classified into categories by their target. A key aspect to understanding the function of antiemetics is the structure of the nervous system signaling pathway as it relates to nausea and vomiting.

read more | 10458 reads

White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications
By Dross at 2007-07-25 22:43
 

Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapyterm-related complication characterized by fever and low white blood cell levels, according to a multi-institutional study led by researchers from the University of Rochester School of Medicine and Dentistry and the Duke Comprehensive Cancer Center.

"Chemotherapy drugs target cancer cells, but they can affect healthy cells as well, including infection-fighting white blood cells," said Nicole M. Kuderer, M.D., a hematology-oncology fellow at Duke and lead author on the publication. "When patients' white blood cell counts drop too low, they are at risk for dangerous infections that can cause death."

read more | 2359 reads

Nanoparticles carry chemotherapy drug deeper into solid tumors
By Dross at 2007-06-27 05:48
 

A new drug delivery method using nano-sized molecules to carry the chemotherapyterm drug doxorubicin to tumors improves the effectiveness of the drug in mice and increases their survival time, according to a study published online June 26 in the Journal of the National Cancer Institute.

In the past, similar drug carriers have improved targeted delivery of the drugs and reduced toxicity, but they sometimes decreased the drugs’ ability to kill the tumor cells. Using a new drug carrier, Ning Tang of the Chinese Academy of Sciences in Beijing and colleagues compared tumor growth and survival in mice that were given doxorubicin in the nanocarriers or on its own.

read more | 1 comment | 2711 reads

Diabetes drug dramatically boosts power of platinum chemotherapy
By Dross at 2007-05-07 23:06
 

BOSTON -- A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber Cancer Institute report.

Combining a platinum chemotherapyterm agent and the diabetes drug rosiglitazone halted or shrank mouse tumors as much as three times more effectively than either of the drugs given alone, according to the article in the May issue of Cancer Cell.

If pairing the drugs has the same synergistic effect in humans, the researchers say, it could improve control of ovarian, lung and other cancers routinely treated with platinum-based chemotherapy, to which tumors eventually become resistant. Moreover, the experiments suggest the combination might extend the use of platinum drugs to other cancers where they haven't previously been shown to be effective.

read more | 4 comments | 3460 reads

Personalized diets may offer relief to advanced cancer patients
By Dross at 2007-03-11 22:25
 

It is well known that cancer patients undergoing chemotherapyterm and radiation therapy often experience nausea and loss of appetite. But until now, few researchers have looked into why this happens and what can be done to ensure that cancer patients maintain a healthy diet during treatment.

Researchers at the University of Alberta studying the effects of chemotherapy and radiation therapy on the senses report that most advanced cancer patients experience unique and persistent taste and smell abnormalities, believed to be a key factor in malnutrition and poor quality of life. The condition, known as chemosensory dysfunction, is believed to last long after patients have finished active chemotherapy or radiation therapy. Taste distortion, heightened sensitivity to odours and a persistent bad taste in the mouth were the most common symptoms described by participants in the recent study conducted by Dr. Wendy Wismer and Dr. Vickie Baracos.

read more | 2519 reads

Increase in Breast Cancer treatment related MDS when GCSF given with Chemo
By Dross at 2007-02-07 05:00
 

Please read the About Us section if you have been diagnosed with Treatment related MDS. Leave your questions in the forums and I will be happy to help you with the latest research.

 

    Women with breast cancer who receive compounds that stimulate white blood cell production to help their bodies better tolerate chemotherapyterm are at an increased risk of developing a type of leukemiaterm or a condition called myelodysplastic syndrome, according to a new study in the February 7 Journal of the National Cancer Institute.

 

read more | 4 comments | 7017 reads

Surgery and adjuvant therapy may work for pancreatic cancer
By Dross at 2007-01-24 02:31
 

 

In the largest single-institution retrospective study to date, researchers at Mayo Clinic Cancer Center have shown that giving patients both radiation and chemotherapyterm after completely removing invasive pancreatic cancer may improve overall survival rates. The study's lead author, a radiation oncology resident in Rochester, Michele Corsini, M.D., presented the findings Saturday, Jan. 20, at the 2007 Gastrointestinal Cancers Symposium. The American Cancer Society reports that while the incidence of pancreatic cancer has decreased over the last few years, it remains the fourth most common cause of cancer-related death. Pancreatic cancer, which has a very poor prognosis, killed more than 32,000 people in the United States last year. "We are constantly looking for ways to improve the prognosis of patients with cancers such as this," says Robert Miller, M.D., co-primary investigator and a radiation oncologist at Mayo Clinic. "Our findings show that surgery should be complemented by both radiation and chemotherapy for best results." In the study, the team of surgeons, oncologists and radiation oncologists from Mayo's Arizona and Minnesota campuses examined the records of 472 consecutively-treated patients. The patients all had surgery with negative margins (some healthy tissue cut out around the cancerous cells), between 1975 and 2005, to remove pancreatic adenocarcinomaterm. They excluded patients who had metastaticterm cancer, tumors that could not be removed or were not removed entirely (positive surgical margins), or indolent (slow growing) tumor types. Ultimately 454 patients were included in the final comparison of patients who received adjuvant therapyterm with those who had not. More than half (274) received concurrent radiation and chemotherapy following surgery and 50 percent survived two years, with 28 percent surviving at least five years. The researchers report more than one-third (180) received no additional therapy after surgery, and the comparative survival rates were significantly less, at 39 percent and 17 percent in two and five years, respectively. Additional chemotherapy after concurrent radiation and chemotherapy seemed to have an even greater effect on survival (61 percent and 34 percent survived two and five years), but only 28 patients received that combination, not enough for the researchers to draw a firm conclusion about its effectiveness. Drs. Miller and Corsini and their fellow researchers think these findings are important to clinicians worldwide. "While long-term outcomes with pancreatic cancer are generally poor," Dr. Corsini says, "our findings show that including both chemotherapy and radiation following surgery may significantly improve patient survival rates." Mayo currently uses a treatment strategy for most patients that includes a combination of radiation and chemotherapy after surgery.

read more | 11 comments | 3386 reads

Prevention of Chemotherapy-Induced Mucositis
By HCat at 2007-01-12 06:22
 


    Mucositisterm from chemotherapyterm can be prevented with cryotherapyterm or chlohexadine rinses. Mucositis is an inflammation (and dying) of the cells that line the mouth, throat, and the rest of the digestive tract. It is a common side effect seen in chemotherapy and radiation treatment but seems to be under reported in statistics. Its symptoms can include ulcers and raw sores in the mouth as well as loss of taste and difficulty eating. A supportive care abstract from the Annals of Oncology recently reported findings at the 31st Congress of the European Society for Medical Oncology (ESMO) (abstract 988 O).

read more | 5919 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 06:46 AM.